A
Alzamend Neuro, Inc. (ALZN)
NCM – Real Time Price. Currency in USD
1.02
-0.03 (-2.86%)
At close: May 12, 2026, 4:00 PM EDT
1.04
+0.02 (1.96%)
After-hours: May 12, 2026, 5:21 PM EDT
Get all premium features to the best stock analysis tool
Find any stock by ticker or company name
NCM – Real Time Price. Currency in USD
1.02
-0.03 (-2.86%)
At close: May 12, 2026, 4:00 PM EDT
1.04
+0.02 (1.96%)
After-hours: May 12, 2026, 5:21 PM EDT
Alzamend Neuro, Inc., a clinical-stage biopharmaceutical company, focuses on developing various products for the treatment of neurodegenerative and psychiatric disorders. Its pipeline includes AL001, which delivers a therapeutic combination of lithium, proline, and salicylate for the treatment of Alzheimer’s, bi-polar disorder, post-traumatic stress disorder, major depressive disorder, other neurodegenerative diseases, and psychiatric disorders; and ALZN002, which uses a method using a mutant-peptide sensitized cell as a cell-based therapeutic vaccine to restore the ability of a patient’s immunological system to combat Alzheimer’s disease. Alzamend Neuro, Inc. was incorporated in 2016 and is headquartered in Atlanta, Georgia.
| Name | Position |
|---|---|
| Mr. David J. Katzoff | Chief Financial Officer |
| Mr. Henry C. W. Nisser Esq. | Executive VP, General Counsel & Director |
| Mr. Kenneth S. Cragun CPA | Senior Vice President of Finance |
| Mr. Milton Charles Ault III | Founder & Vice Chairman |
| Mr. Stephan Jackman | CEO & Director |
| Date | Type | Document |
|---|---|---|
| 2026-04-17 | 8-K | p4172668k.htm |
| 2026-03-20 | 8-K | g3202628k.htm |
| 2026-03-11 | 10-Q | z3626110q.htm |
| 2026-03-06 | 8-K | d362618k.htm |
| 2026-02-26 | DEF 14A | i225262def14a.htm |
| 2026-02-09 | PRE 14A | g29260pre14a.htm |
| 2025-12-09 | 10-Q | r12325010q.htm |
| 2025-11-18 | 8-K | x11172508k.htm |
| 2025-10-14 | 8-K | b10142528k.htm |
| 2025-10-09 | 8-K | o1082528k.htm |